TLR9 and neoplasm: To enhance the immunogenicity of tumor cell lysates, Callmann et al. [70] developed liposomal SNA architectures that were prepared from 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), loaded with tumor cell lysates derived from triple-negative breast cancer (TNBC) cell lines, and decorated with a shell of radially oriented TLR9-agonistic CpG oligonucleotides (Figure 3).